No Data
No Data
Congruence and Ono Announce Multi-Target Research Collaboration to Generate Small Molecule Correctors for the Treatment of Cancer
Equillium Shares Are Trading Lower After the Company Announced Ono Pharmaceutical Has Made the Business Decision to Allow the Expiration of Its Option to Acquire Equillium's Rights to Itolizumab
Ono Pharmaceutical Makes Strategic Business Decision to Allow Itolizumab Option to Expire
Ono Pharmaceutical 1H Net Y41.64B Vs Net Y74.49B
Market Chatter: LigaChem Biosciences Signs $700 Million License Deal for Anti-Cancer Drug
Kinaxis Brief: Says to Bolster Supply Chain Operations of Ono Pharmaceutical; No Financial Details Given
No Data